GDMT, guideline-directed medical therapy; HR, hazard ratio; CI, confidence interval. Figure S1 . Risk of mortality according to blood pressure categories. HR, hazard ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure. Figure S2 . Prescription rates of GDMT according to age and EF category. GDMT, guideline directed medical therapy; EF, ejection fraction; HF, heart failure; HFrEF, HF with reduced EF; HFpEF, HF with preserved EF; RASi, renin-angiotensin system inhibitor; AA, aldosterone antagonist. Figure S3 . Kaplan-Meier curves for all-cause mortality according to BP and beta-blocker use. BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure. Figure S4 . Kaplan-Meier curve for cumulative all-cause mortality according to use of aldosterone antagonists at discharge in octogenarians with HFrEF. AA, aldosterone antagonist; HFrEF, heart failure and reduced ejection fraction. Figure S5 . Kaplan-Meier curve for 6-month HF readmissions according to use of GDMT in octogenarians with HFrEF. HF, heart failure; GDMT, guideline directed medical therapy; HFrEF, heart failure and reduced ejection fraction; RAS, renin-angiotensin system; AA, aldosterone antagonist.
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